Industry
Biotechnology
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Luke J Jacobi
August 14, 2023 | 12:31 pm
Portfolio Pulse from richadhand@benzinga.com
August 14, 2023 | 12:17 pm
Portfolio Pulse from richadhand@benzinga.com
August 14, 2023 | 10:29 am
Portfolio Pulse from Benzinga Newsdesk
August 10, 2023 | 11:29 am
Portfolio Pulse from Benzinga Newsdesk
July 31, 2023 | 4:22 pm
Portfolio Pulse from Benzinga Insights
July 26, 2023 | 6:01 pm
Portfolio Pulse from richadhand@benzinga.com
July 26, 2023 | 10:24 am
Portfolio Pulse from Benzinga Newsdesk
July 25, 2023 | 12:04 pm
Portfolio Pulse from Chris Katje
July 18, 2023 | 4:04 pm
Portfolio Pulse from Vandana Singh
July 17, 2023 | 6:39 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.